Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Redifferentiation of a RET-Fusion, Radioiodine-Refractory, Differentiated Thyroid Cancer with Selpercatinib: Flip-Flop Between [F]FDG PET/CT and I Posttreatment Scanning.
J Nucl Med
January 2025
Endocrinology Department, Lille University Hospital, Lille, France
Clinico-pathological factors and [F]FDG PET/CT metabolic parameters for prediction of progression-free survival in radioiodine refractory differentiated thyroid carcinoma.
BMC Med Imaging
December 2024
Department of Nuclear Medicine, Hospital 108, Hanoi, Vietnam.
Objective: Identifying prognostic markers for clinical outcomes is crucial in selecting appropriate treatment options for patients with radioiodine-refractory (RAI-R) differentiated thyroid carcinoma (DTC). The aim of this study was to investigate the prognostic value of clinico-pathological features and semiquantitative [F]FDG PET/CT metabolic parameters in predicting progression-free survival (PFS) in DTC patients with RAI-R.
Patients And Methods: This prospective cohort study included 110 consecutive RAI-R DTC patients who were referred for [F]FDG PET/CT imaging.
Modeling Clinical Radioiodine Uptake By Using Organoids Derived From Differentiated Thyroid Cancer.
Endocrinology
November 2024
Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610000, China.
Article Synopsis
- The study focuses on radioiodine-refractory differentiated thyroid cancer (RAI-R DTC), which is a major cause of thyroid-related deaths and has limited models for predicting iodine uptake.
- Researchers created a primary tumor-derived organoid model from 20 DTC patients to assess and predict radioiodine uptake, comparing the organoids' properties to the original tumor tissue.
- The results showed that RAI-avid organoids had significantly higher iodine uptake than RAI-R organoids, with a predictive accuracy of 95% for determining iodine-refractory cases, and highlighted the potential of using tyrosine kinase inhibitors to resensitize iodine uptake in certain patients.
The impact of qualitative [18F]FDG PET/CT in predicting clinical outcomes of post-surgical differentiated thyroid cancer patients with elevated thyroglobulin and negative radioiodine whole-body scan.
BMC Surg
November 2024
Department of Nuclear Medicine, Tran Hung Dao Hospital (Hospital 108), Hanoi, Vietnam.
Background: [F]FDG PET/CT has been widely used as a diagnostic tool in detection and localization of recurrent non-avid radioiodine lesions in post-operative differentiated thyroid cancer (DTC) patients with elevated serum thyroglobulin but negative radioiodine whole-body scan (TENIS) syndrome. The aim of our study was to evaluate the role of [F]FDG PET/CT in prediction on outcomes of these DTC patients.
Methods: Post-operative DTC patients with TENIS syndrome were collected in the department of nuclear medicine, Hospital 108 from 2019 to 2023.
Detection and quantification of small and low-uptake lesions for differentiated thyroid carcinoma using non-time-of-flight iodine-124 PET/MRI.
Med Phys
November 2024
High-Field and Hybrid MR Imaging, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Article Synopsis
- 124-iodine (I) is essential for PET diagnostics and therapy in differentiated thyroid cancer (DTC), but detecting small lesions (<10 mm) poses significant challenges due to low iodine uptake.
- The study aimed to evaluate the effectiveness of non-time-of-flight (TOF) PET/MRI in identifying and quantifying small DTC lymph node lesions under difficult imaging conditions.
- Results indicated that longer acquisition times, higher activity concentrations, and advanced reconstruction algorithms improved lesion visibility, with the smallest detectable size of 3.7 mm only visible under optimal settings.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!